U.S. Markets closed

Exelixis, Inc. (EXEL)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
23.78-0.29 (-1.20%)
At close: 4:00PM EDT

24.30 0.52 (2.19%)
After hours: 7:45PM EDT

People also watch
  • Okay sports fans,
    From a very experienced biotech investor of multiple decades and dozens of biotech investments, it’s show me the money. More specifically it’s show me the revenue. You can see here from this chart the high correlation between market cap and revenue.
    In billions MCap Revenue
    AMGN 134 22.6
    CELG 97 13.2
    BIIB 60 11.4
    REGN 41 5.5
    VRTX 34 2.2
    ALXN 28 3.4
    INCY 28 1.4
    BMRN 17 1.3
    SGEN 9 0.5
    IONS 7 0.37
    EXEL 7 0.36
    KITE 5 0.2

    So here is the point. If you expect cabo to be approved in first line RCC, with Sutent revenues now near a billion and if any of the combination studies too numerous to mention come to fruition, I don’t think an expectation of EXEL total revenues including cobi of 1.5billion to be outlandish. Therefore from the chart, I also think a market cap of 20 billion is very plausible. A 20 billion market cap puts EXEL around 70. (go Hairy! Kaboom!) So you can root for a short term bump for a buyout if you want. A very generous 35-40 percent market premium for a buyout only puts you at 33 to 34 dollars. Personally I’d rather wait a little longer for 70 and have a chance for 100 plus.
    I am long EXEL. I composed this myself and did it pretty fast so there could be errors in market cap and revenue estimates which are approximate. However, I think it’s accurate enough to draw the logical conclusions. I am not receiving any compensation for this and have no relationship with the company other than as a stockholder.
  • Russell 2000 rebalancing, happens once a year at end of session.
  • Very little retail investor action at these levels. Big boy money is pouring in and will take this to the moon. We are still somewhat under valued considering a possible First line treatment for Kidney Cancer.
  • I said chill out last week when it was $19 and say the same now. It may be bumpy, but the ride should get us in 2-5 years north of $40!! Alone or BO!! Just add to your positions when you can. 🍾🍾
  • A classic "coiled spring" scenario. I have a feeling while discussions are underway, a lot is still contingent upon sNDA filing for first line RCC and definitive (positive) interim results in HCC. EXEL management has to wait rather than hastily take the offer. Cabo as it is well positioned to grow very well and company has plenty of cash and future positive cash flow to support operations, so they should be shrewd and wait a few more months. The buy-out thought seems more and more probable in the $50+ range. But if EXEL can keep itself independent we may well be looking at $100 in 2-3 years. That's a fantastic return for all of us long time holders....for many a real possibility of retirement!!
  • First resistance is 24.63 we need to take that out if we are to move higher today, 2nd resistance level is 25.20.
  • From my Level II, I can see a BIG GUY has manipulated the price in the last 3, 4 minutes SOLD 1,433,595 shares to brought the price down from $24.52 to $23.78. This BIG GUY is criminal trader.
  • Folks the fun is just starting. The action clearly indicates some talks are going on behind the scenes. This type of movement in share price in three days is more that just the data release news from Monday. We are clearly in the line of sight for some big pharma for a takeout. Dawn, you were 100% correct we will be bought give the action (this is just a pre-leakage). I suspect we will see a $3-$4 movement when the actual leak takes place otherwise we will just wake up one morning and read that EXEL has agreed to "XYZ" offer of $38-$40
  • Looks like the biotech sector continues its momentum today......EXEL is still very cheap here at $24 as more positive news is not too far away (including another strong qtl'y numbers on Aug 3rd)!
  • WHEN??
  • Let's hope today will see a new 12 month high!!
  • Most of you guys are riding OMER too, right? Love EXEL and OMER.
  • $25 today? Any thoughts......
  • Shorties -- give it up! efficacy will kill you!
  • Big boys really know how to make money on promising/growing companies. They take it down 25% in 5 weeks (after great earnings) and then wait for some news and bring it back up 16% in two days, making a killing on both sides. Us longs awaiting the "bigger" news can only watch from the sidelines and chuckle (and a few of us with dry powder added while it was down)!
  • First time that EXEL advanced on a 12%+ ... hold for low $30's then a buyout will come! kaboom! no less than $70's by the Fall
  • New 52 week high in the cross hairs and hopefully hits today. The current qtr will probably be stronger than last qtr (which was their first profitable qtr operationally), so would think we're positioned to be near 27-28 range after earnings on Aug 3rd!
  • Buy me a beer! KABOOM! we will see $25's soon!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! boom!
  • Exelixis has generated explosive sales growth over the last four quarters, ranging from 354% to 680%. Quarterly revenue has risen from $36 million to nearly $81 million during that time.
    Earnings growth has ranged from 105% to 167% over the last three reports, but note that those gains are based on comparisons to year-over-year quarters with no earnings.
    Institutional investors have taken notice, and the number of funds with a position in Exelixis has risen in each of the last four quarters.
    The stock currently sports a B+ Accumulation-Distribution Rating and 1.4 Up-Down Volume Ratio.
    Biotech Breakout Ahead?
    As of Wednesday's close, Exelixis was up nearly 25% for the week, with its relative strength line trending sharply higher.
    Volume has been well above average in recent days as the stock has retaken its 50-day line and continued to climb.

    Exelixis made a huge run from a breakout last June, but the stock reset its base count in May when it undercut the low in the prior consolidation. That means its current cup-shaped pattern is considered a first-stage base.
    The potential buy point is 24.95.
    On Thursday afternoon, Exelixis had come up from earlier lows and was down just fractionally. Volume was trending about 40% above average.
    Look for the biotech boom to continue and for Exelixis to jump past the entry in heavy volume.
  • volume is good I do not understand why the stock is not moving higher any ideas?